JNJ vs SY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.
SY presents a contradictory profile: a stable Piotroski F-Score of 5/9 and strong liquidity, contrasted by a catastrophic earnings track record. While the company maintains a very low Price-to-Sales ratio (0.19) and healthy revenue growth (24.8% YoY), it has failed to beat earnings estimates in the last four quarters with massive negative surprises. The technical trend is completely bearish (0/100), and the shift from profitability in 2024 back to significant losses in 2025-2026 suggests a failing operational turnaround.
Compare Another Pair
Related Comparisons
JNJ vs SY: Head-to-Head Comparison
This page compares Johnson & Johnson (JNJ) and So-Young International Inc. (SY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.